Sustained generic pricing pressure
Pricing pressure across the generic portfolio continues, with no clear timeline for stabilization; management hopes for normalization in 6-12 months.
high · management_commentary
Divi's Laboratories — Q2 FY25
Divis Labs reported a strong Q2 FY25 with PAT surging 46.6% YoY to INR 510 Cr, driven by robust custom synthesis demand and operational efficiencies.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Red Sea logistics disruptions
Extended shipping routes due to Red Sea attacks have increased transit times from 45 to 70 days and raised logistics costs, impacting supply chain efficiency.
medium · management_commentaryRaw material cost volatility
While raw material prices have stabilized, they remain sensitive to Middle East developments and crude oil fluctuations, posing a risk to margins.
medium · management_commentaryUnit 3 ramp-up and regulatory approvals
The greenfield Unit 3 will take time to achieve regulatory approvals and full utilization, with initial production focused on non-regulatory products.
medium · analyst_question